Further supporting the shared biology between CHEK2* and TP53 mutant BCs is the observation that CHEK2* pBCs had the highest WGD frequency among the subgroups, a feature enriched among TP53 mutant cancers [50]. This evidence concerns the gene CHEK2 and cancer.